EGFR and lung carcinoma: For instance, growing evidence indicates that APOBEC mutations are prevalent in acquired EGFR-TKI-resistant NSCLC, underscoring the role of APOBEC enzymes in the evolution of EGFR-mutant lung cancer and their potential as therapeutic targets for addressing tumor heterogeneity [96,97].